Calgary healthtech startup Nimble Science has raised $2.7 million to commercially scale their revolutionary multi-omic SIMBA GI Health Platform to food, diagnostic, and drug companies.
Nimble Science is led by experienced medtech, wearable and ingestible executives, along with advisors spanning GI, microbiome & digital health.
This funding brings Nimble Science out of stealth mode to enable academia, government and industry to unlock critical health data insights in the previously out of reach small intestine.
Over fifteen chronic diseases are associated with dysbiosis of the small intestine, representing a 75 billion dollar total addressable market. Nimble Science’s consumer-friendly SIMBA™ capsule finally enables small intestine multi-omic microbiome data collection to empower novel consumer product, therapeutic and diagnostic development.
Fusion Fund, of Palo Alto, California led the oversubscribed financing round, which included new investors First Spark Ventures, Alumni Ventures, Joyance Partners, Adara VC and Startup TNT and TNT Capital, with follow-on funding from pre-seed partners, which include BoxOne Ventures, Threshold Impact, BlueSky Equities, UCeed Child Health and Wellness Fund and angels.
“The time is now for our SIMBA product to revolutionize the field by providing access to this novel dataset. The introduction of endoscopy-quality liquid biopsies collected from large cohorts within the home is a game changer for understanding, monitoring and treating a variety of gut-related conditions”, says Nimble CEO Dr. Sabina Bruehlmann.
Funds will be deployed to advance the SIMBA GI Health diagnostic test platform, grow commercial research partnerships spanning consumer products, academia, government and drug companies, as well as expand Nimble Science’s team.